{"id":"basal-insulin-and-bolus-insulin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Basal insulin provides steady background insulin levels to suppress hepatic glucose production and maintain fasting blood glucose, while bolus insulin is administered at mealtimes to counteract postprandial glucose excursions. Together, this regimen approximates the body's natural biphasic insulin secretion pattern, improving overall glycemic control in insulin-dependent diabetes.","oneSentence":"Basal-bolus insulin therapy mimics physiological insulin secretion by combining long-acting basal insulin for fasting glucose control with rapid-acting bolus insulin for postprandial glucose management.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:21.223Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus requiring intensive insulin therapy"}]},"trialDetails":[{"nctId":"NCT06762314","phase":"PHASE2","title":"Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2025-01-20","conditions":"Diabetes","enrollment":105},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT07423559","phase":"NA","title":"Relapse Among Diabetic Ketoacidosis Patients Maintained Basal Bolus Insulin Administration in Combination With Continuous Intravenous Insulin Infusion VS Non Maintaining Basal Insulin Patients","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-11-30","conditions":"Diabetic Ketoacidosis, Insulin, Intensive Care Unit Stay","enrollment":100},{"nctId":"NCT05785832","phase":"NA","title":"A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tandem Diabetes Care, Inc.","startDate":"2023-06-01","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":319},{"nctId":"NCT06334068","phase":"NA","title":"SHOrt-term Glycemic Control for Reducing Post-SURGical Complications","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2024-05-08","conditions":"Diabetes, Uncontrolled Diabtetes","enrollment":53},{"nctId":"NCT07282639","phase":"NA","title":"App-Based Certified Diabetes Education Therapy (AB-CDE)","status":"NOT_YET_RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2026-01-15","conditions":"Type 1 Diabetes (T1D)","enrollment":99},{"nctId":"NCT05305794","phase":"PHASE3","title":"Effect of Weekly GLP1 Agonist Treatment in \"Double Diabetes\"","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2022-07-12","conditions":"Double Diabetes","enrollment":76},{"nctId":"NCT04880850","phase":"PHASE3","title":"A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-05-14","conditions":"Diabetes Mellitus, Type 2","enrollment":582},{"nctId":"NCT04016558","phase":"NA","title":"Behavioral Approaches to Reducing Diabetes Distress and Improving Glycemic Control","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2019-09-15","conditions":"Type 1 Diabetes, Diabetes Distress","enrollment":296},{"nctId":"NCT06420518","phase":"","title":"Accuracy of a Continuous Ketone Monitoring (CKM) System in Individuals With Type 1 Diabetes on Insulin Pump Therapy.","status":"COMPLETED","sponsor":"McGill University","startDate":"2024-04-30","conditions":"type1diabetes","enrollment":16},{"nctId":"NCT06529705","phase":"NA","title":"Performance and Safety Evaluation of the EkiYou V2 Application in Patients With Diabetes Using Multiple Daily Insulin Injections (EkiYou-Study1)","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2024-08-19","conditions":"Diabetes Type 1, Diabetes Type 2 on Insulin, Pancreatogenous Diabetes","enrollment":21},{"nctId":"NCT06627517","phase":"NA","title":"Safety and Effectiveness of the Luna System in People With Type 1 Diabetes Mellitus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Luna Diabetes","startDate":"2024-11-22","conditions":"Type 1 Diabetes Mellitus, Sleep Quality","enrollment":120},{"nctId":"NCT06238778","phase":"PHASE2","title":"Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diasome Pharmaceuticlas, Inc.","startDate":"2024-01-23","conditions":"Diabetes Mellitus, Type 1","enrollment":227},{"nctId":"NCT07066891","phase":"NA","title":"Validation of Insulin Dose Prediction Model Based on Artificial Intelligence Algorithm","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-07-15","conditions":"Diabetes Mellitus, Type 2 Diabetes","enrollment":400},{"nctId":"NCT06605859","phase":"","title":"DigiDiab Pilot Spain - Nursing Home and Domiciliary Nursing Care","status":"RECRUITING","sponsor":"Medical University of Graz","startDate":"2025-04-08","conditions":"Type 2 Diabetes","enrollment":40},{"nctId":"NCT06616779","phase":"","title":"DigiDiab Evaluation Domiciliary Nursing Care","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2024-11-30","conditions":"Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes, Insulin Requiring","enrollment":40},{"nctId":"NCT06406439","phase":"NA","title":"DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients","status":"COMPLETED","sponsor":"G2e Co., Ltd","startDate":"2024-05-21","conditions":"Diabetes (Insulin-requiring, Type 1 or Type 2), Pancreatogenic Diabetes Mellitus","enrollment":120},{"nctId":"NCT06738849","phase":"NA","title":"EkiYou-Study-2 : A National Multicentric Trial of the EkiYou Application for Insulin Bolus Calculation","status":"RECRUITING","sponsor":"DiappyMed","startDate":"2024-11-05","conditions":"Diabetes Type 1, Diabetes Type 2 on Insulin, Pancreatogenous Diabetes","enrollment":154},{"nctId":"NCT07004153","phase":"NA","title":"A Study of DIA:CONN P8 Smart Insulin Pen With CGM-Based Coaching in Patients With Type 1 or Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"G2e Co., Ltd","startDate":"2025-06","conditions":"Diabetes Mellitus","enrollment":152},{"nctId":"NCT06962410","phase":"NA","title":"Hybrid Closed-Loop in Diabetes Post-Kidney Transplant: A Randomized Trial","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-04-01","conditions":"Diabetes Mellitus Patients With Kidney Transplantation","enrollment":30},{"nctId":"NCT06941675","phase":"NA","title":"Hybrid Closed-Loop System in LADA Patients: A Randomized Trial","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-04-01","conditions":"Latent Autoimmune Diabetes in Adults (LADA)","enrollment":50},{"nctId":"NCT06909071","phase":"NA","title":"Hybrid Closed-Loop System in Neurosurgical Perioperative Hyperglycemia: An Open RCT","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-04-15","conditions":"T2DM Patients With Traumatic Brain Injury","enrollment":40},{"nctId":"NCT04617795","phase":"NA","title":"Omnipod® 5 Automated Insulin Delivery System in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Insulet Corporation","startDate":"2020-11-23","conditions":"Type 2 Diabetes Mellitus","enrollment":25},{"nctId":"NCT05243628","phase":"PHASE4","title":"Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2022-03-31","conditions":"Type 1 Diabetes","enrollment":33},{"nctId":"NCT06855615","phase":"PHASE4","title":"Comparison of Thrice-Daily Premixed Human Insulin with Basal-Bolus Therapy Among Patients with Poorly Controlled Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Hospital Sultanah Aminah Johor Bahru","startDate":"2020-10-01","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":44},{"nctId":"NCT04538352","phase":"PHASE4","title":"Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2021-01-18","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT02542631","phase":"NA","title":"Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Calibra Medical, Inc.","startDate":"2015-08-01","conditions":"Diabetes Mellitus, Type 2","enrollment":278},{"nctId":"NCT06638567","phase":"NA","title":"Postoperative Basal Bolus or Sliding Scale Insulin Regimen in DM2 and Its Effect on Surgical Site Infections.","status":"RECRUITING","sponsor":"Abraham Hulst, MD, PhD","startDate":"2025-01-03","conditions":"Diabetes Mellitus, Type 2, Surgical Site Infection","enrollment":1008},{"nctId":"NCT04016662","phase":"PHASE4","title":"Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D)","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2020-09-28","conditions":"Type 1 Diabetes Mellitus","enrollment":82},{"nctId":"NCT03087032","phase":"PHASE4","title":"Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2019-01-10","conditions":"Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic)","enrollment":164},{"nctId":"NCT05768191","phase":"PHASE4","title":"Comparative Efficacy of a Two Daily Mixed Insulin Injection Versus a Basal-bolus Scheme With Human Insulin","status":"COMPLETED","sponsor":"Université NAZI BONI","startDate":"2023-06-15","conditions":"Type 1 Diabetes","enrollment":22},{"nctId":"NCT05218915","phase":"PHASE4","title":"Basal Plus GLP1-ra on Glycemic Variability in CKD","status":"COMPLETED","sponsor":"Elaine Chow","startDate":"2022-01-28","conditions":"Diabetes Mellitus, Diabetic Kidney Disease","enrollment":95},{"nctId":"NCT06487598","phase":"NA","title":"To Evaluate add-on Effect of Nisha-Amalaki Tablets Along With Insulin on Glycemic Control in Type 1 Diabetes Patients (RCTNA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hirabai Cowasji Jehangir Medical Research Institute","startDate":"2024-07-01","conditions":"Type 1 Diabetes","enrollment":70},{"nctId":"NCT06600776","phase":"PHASE4","title":"Mealtime or Post-meal Dosing of URLi in Medtronic 780G Hybrid Closed Loop System","status":"NOT_YET_RECRUITING","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2024-10-06","conditions":"Type 1 Diabetes (T1D)","enrollment":50},{"nctId":"NCT06607224","phase":"NA","title":"Effect of the Use of Continuous Glucose Monitoring Versus Standard Glycemic Control in Hospitalized Patients with Type 2 Diabetes.","status":"COMPLETED","sponsor":"Hospital General Universitario Gregorio Marañon","startDate":"2022-01-10","conditions":"Diabetes Mellitus Type 2, Hospitalization","enrollment":40},{"nctId":"NCT05118945","phase":"","title":"Study on the Use of the Insulin Pump Tandem X:2 With Control IQ Algorithm - Update","status":"COMPLETED","sponsor":"Kinderkrankenhaus auf der Bult","startDate":"2021-03-03","conditions":"Type 1 Diabetes, Insulin Therapy","enrollment":50},{"nctId":"NCT02558491","phase":"NA","title":"Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM","status":"COMPLETED","sponsor":"Daniel Chernavvsky, MD","startDate":"2015-09","conditions":"Type 1 Diabetes Mellitus","enrollment":33},{"nctId":"NCT04123054","phase":"NA","title":"A Novel mHealth Application Guided by an Optimization Algorithm for T1D Sensor-Augmented Insulin Injection Users","status":"COMPLETED","sponsor":"McGill University","startDate":"2020-03-05","conditions":"Diabetes Mellitus, Diabetes Mellitus, Type 1","enrollment":84},{"nctId":"NCT06046417","phase":"PHASE2, PHASE3","title":"A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2023-11-30","conditions":"type1diabetes, Diabetes Mellitus, Type 1","enrollment":30},{"nctId":"NCT04460326","phase":"PHASE3","title":"Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2020-12-07","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":137},{"nctId":"NCT06297980","phase":"NA","title":"Impact of MEnstruation on Glycemic Response and Exercise In Females With Type 1 Diabetes","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-03-15","conditions":"Type 1 Diabetes, Hypoglycemia, Hyperglycaemia Due to Type 1 Diabetes Mellitus","enrollment":150},{"nctId":"NCT00447382","phase":"PHASE3","title":"Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-03","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":330},{"nctId":"NCT01524705","phase":"PHASE4","title":"FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2012-08","conditions":"Type 2 Diabetes","enrollment":102},{"nctId":"NCT05360537","phase":"PHASE4","title":"Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2021-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT04019821","phase":"PHASE4","title":"Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2020-01-01","conditions":"Diabetes Mellitus, Type 1","enrollment":72},{"nctId":"NCT00313742","phase":"PHASE4","title":"The Effect of Exercise on Blood Glucose Levels in Patients With Type 1 Diabetes: A Comparison of 3 Long-acting Insulins","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-04","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":51},{"nctId":"NCT05199714","phase":"NA","title":"A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2022-02-21","conditions":"Type 1 Diabetes","enrollment":12},{"nctId":"NCT05457933","phase":"PHASE4","title":"Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2022-07-29","conditions":"Type2diabetes, Coronary Artery Disease","enrollment":250},{"nctId":"NCT05262595","phase":"PHASE1","title":"A Study to Look at How Insulin NNC0471-0119 Works in the Body in People With Type 1 Diabetes When Injected by Insulin Pump","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-03-03","conditions":"Diabetes Mellitus, Type 1","enrollment":19},{"nctId":"NCT05067270","phase":"PHASE1","title":"A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-10-22","conditions":"Type 1 Diabetes Mellitus","enrollment":40},{"nctId":"NCT06057077","phase":"PHASE1, PHASE2","title":"Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus","status":"UNKNOWN","sponsor":"Ministry of Health, Saudi Arabia","startDate":"2024-01-01","conditions":"Type 1 Diabetes","enrollment":120},{"nctId":"NCT02408120","phase":"PHASE4","title":"Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-10","conditions":"Diabetes Mellitus, Type 2","enrollment":226},{"nctId":"NCT03737240","phase":"PHASE3","title":"IDegLira HIGH Trial","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-01-15","conditions":"Diabetes Mellitus","enrollment":145},{"nctId":"NCT00357890","phase":"NA","title":"Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2005-12","conditions":"Diabetes Mellitus, Insulin-Dependent","enrollment":12},{"nctId":"NCT01308437","phase":"PHASE3","title":"Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics","status":"TERMINATED","sponsor":"Wockhardt","startDate":"2011-03","conditions":"Type I Diabetes","enrollment":134},{"nctId":"NCT00788840","phase":"PHASE4","title":"Detemir Energy Expenditure Study","status":"COMPLETED","sponsor":"University of Surrey","startDate":"2008-01","conditions":"Type 2 Diabetes Mellitus, Obesity","enrollment":30},{"nctId":"NCT03387787","phase":"PHASE2, PHASE3","title":"Evaluation of Glycaemic Control Using GlucoTab® With Insulin Degludec in Hospitalized Patients With Diabetes Mellitus Type 2","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2018-01-30","conditions":"Type 2 Diabetes Mellitus","enrollment":15},{"nctId":"NCT04243629","phase":"NA","title":"Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes","status":"UNKNOWN","sponsor":"McGill University","startDate":"2021-11-12","conditions":"Diabetes Mellitus, Type 1, Type 1 Diabetes, Postprandial Hyperglycemia","enrollment":26},{"nctId":"NCT05767255","phase":"PHASE3","title":"Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue","status":"UNKNOWN","sponsor":"Hospital Universitario San Ignacio","startDate":"2022-12-01","conditions":"Diabetes Mellitus, Type 2 Treated With Insulin","enrollment":66},{"nctId":"NCT04605991","phase":"PHASE3","title":"A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-11-04","conditions":"Type 2 Diabetes","enrollment":187},{"nctId":"NCT03093636","phase":"NA","title":"Efficacy of inControl Advice: A Decision Support System (DSS) for Diabetes","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2017-04-17","conditions":"Type1 Diabetes Mellitus","enrollment":80},{"nctId":"NCT04163874","phase":"NA","title":"Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas","status":"COMPLETED","sponsor":"McGill University","startDate":"2020-02-14","conditions":"Type 1 Diabetes, Type 1 Diabetes Mellitus, Hyperglycemia, Postprandial","enrollment":36},{"nctId":"NCT05184868","phase":"PHASE1","title":"AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study","status":"COMPLETED","sponsor":"Arecor Limited","startDate":"2022-01-03","conditions":"Diabetes Mellitus, Type 1","enrollment":24},{"nctId":"NCT01890954","phase":"NA","title":"Optimizing Closed-Loop Control of Type 1 Diabetes Mellitus in Adolescents","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2013-08","conditions":"Diabetes Mellitus, Type 1","enrollment":17},{"nctId":"NCT05429359","phase":"NA","title":"cArdiopulmonary exerCise Test Assessing Multiple biOmarkers and Hormones iN Type 1 diabetEs Under Different Circumstances","status":"UNKNOWN","sponsor":"University Hospital, Antwerp","startDate":"2022-10-01","conditions":"Diabetes Mellitus, Type 1","enrollment":50},{"nctId":"NCT03557151","phase":"NA","title":"Transdisciplinary Versus Usual Care for Type1 Diabetes in Adolescence","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2018-07-13","conditions":"Type 1 Diabetes Mellitus","enrollment":230},{"nctId":"NCT04871958","phase":"NA","title":"Individualized, Technological Interventions for Diabetes Care in the COVID-19 Ward","status":"TERMINATED","sponsor":"Federico II University","startDate":"2021-03-19","conditions":"Diabetes Mellitus, Covid19","enrollment":66},{"nctId":"NCT03557892","phase":"NA","title":"Sensor-augmented Pump Versus Multiple Daily Injections With Degludec as Basal Insulin for Insulin Therapy in Type 1 Diabetes","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2018-04-01","conditions":"Diabetes Mellitus, Type 1","enrollment":28},{"nctId":"NCT04726163","phase":"NA","title":"Tele-expertise in Patients With Diabetes Hospitalized for Covid-19 Infection","status":"TERMINATED","sponsor":"University Hospital, Strasbourg, France","startDate":"2021-01-29","conditions":"Diabetic Patient (Type 1,2, MODY, Secondary) or With Corticosteroid-induced Diabetes Following Initiation of Corticosteroid Treatment","enrollment":48},{"nctId":"NCT03436498","phase":"PHASE1","title":"Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-05-10","conditions":"Type 1 Diabetes Mellitus","enrollment":45},{"nctId":"NCT03406000","phase":"PHASE4","title":"Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-01-22","conditions":"Type I Diabetes Mellitus","enrollment":170},{"nctId":"NCT02194595","phase":"PHASE3","title":"Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2014-09","conditions":"Type 2 Diabetes","enrollment":105},{"nctId":"NCT03895515","phase":"","title":"Effect of Fiasp® in Type 1 Diabetes Treatment","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-01-03","conditions":"Diabetes Mellitus, Type 1","enrollment":178},{"nctId":"NCT03336528","phase":"PHASE4","title":"Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-01-02","conditions":"Type 2 Diabetes","enrollment":180},{"nctId":"NCT03547427","phase":"NA","title":"Glucagon Counterregulation in Type 1 Diabetes","status":"TERMINATED","sponsor":"University of Virginia","startDate":"2018-05-20","conditions":"Type 1 Diabetes Mellitus","enrollment":13},{"nctId":"NCT04847778","phase":"NA","title":"Assess the Impact of Insulclock on Glycemic Variability and Treatment Compliance in Uncontrolled DM1 Patients","status":"COMPLETED","sponsor":"Hospital General de Segovia","startDate":"2021-03-01","conditions":"Diabetes Mellitus, Type 1","enrollment":80},{"nctId":"NCT00591227","phase":"PHASE4","title":"Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2008-05","conditions":"Type 2 Diabetes Mellitus","enrollment":176},{"nctId":"NCT04533945","phase":"NA","title":"Feasibility of Using the CGM During TOC From in Persons With T2D Using Insulin","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2020-03-25","conditions":"Diabetes, Type 2 Diabetes","enrollment":40},{"nctId":"NCT05152121","phase":"NA","title":"Additional Insulin for High Fat/Protein in Type 1 Diabetes","status":"COMPLETED","sponsor":"Ege University","startDate":"2017-07-01","conditions":"Type 1 Diabetes, Adolescent","enrollment":20},{"nctId":"NCT04323462","phase":"PHASE4","title":"Intensive Glycemic Control For Diabetic Foot Ulcer Healing","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2021-10-01","conditions":"Diabetic Foot Ulcer","enrollment":326},{"nctId":"NCT01512654","phase":"NA","title":"Personalized Glucose Predictive and Therapy Advisory System - DIAdvisor 2","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2008-09","conditions":"Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1","enrollment":60},{"nctId":"NCT01555788","phase":"NA","title":"DiaPort Closed-Loop Artificial Pancreas","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2012-02","conditions":"Type 1 Diabetes Mellitus","enrollment":10},{"nctId":"NCT03670641","phase":"PHASE4","title":"Remission Through Early Monitored Insulin Therapy - Duration Month","status":"COMPLETED","sponsor":"Sandra Sobel","startDate":"2019-03-26","conditions":"Type 2 Diabetes Mellitus","enrollment":10},{"nctId":"NCT03001323","phase":"NA","title":"Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis","status":"TERMINATED","sponsor":"Hennepin Healthcare Research Institute","startDate":"2017-01","conditions":"Diabetes Mellitus","enrollment":27},{"nctId":"NCT04347252","phase":"PHASE1","title":"Glucagon Regulation of Glucose Metabolism","status":"COMPLETED","sponsor":"David D'Alessio, M.D.","startDate":"2019-09-24","conditions":"Insulin Secretion","enrollment":19},{"nctId":"NCT04542213","phase":"PHASE3","title":"Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19","status":"COMPLETED","sponsor":"Hospital Regional de Alta Especialidad del Bajio","startDate":"2020-08-01","conditions":"Hyperglycemia, Covid19","enrollment":70},{"nctId":"NCT01484457","phase":"EARLY_PHASE1","title":"Controlled Insulin Delivery: Combining Technology With Treatment","status":"COMPLETED","sponsor":"Sansum Diabetes Research Institute","startDate":"2008-07","conditions":"Diabetes Mellitus, Type 1","enrollment":19},{"nctId":"NCT04409587","phase":"PHASE4","title":"Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump","status":"COMPLETED","sponsor":"Mountain Diabetes and Endocrine Center","startDate":"2018-04-12","conditions":"Type1 Diabetes Mellitus","enrollment":59},{"nctId":"NCT04739241","phase":"PHASE4","title":"Premixed vs Basal Bolus Insulin Therapy in Older Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Consorci Sanitari Integral","startDate":"2014-01-24","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":60},{"nctId":"NCT02229227","phase":"PHASE3","title":"Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-11-21","conditions":"Diabetes Mellitus, Type 2","enrollment":814},{"nctId":"NCT04414579","phase":"PHASE4","title":"The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus","status":"UNKNOWN","sponsor":"Mountain Diabetes and Endocrine Center","startDate":"2019-03-27","conditions":"Type 1 Diabetes Mellitus","enrollment":45},{"nctId":"NCT04196231","phase":"PHASE4","title":"Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2019-11-27","conditions":"Type 2 Diabetes","enrollment":258},{"nctId":"NCT01957930","phase":"NA","title":"Intensive Insulin Treatment and Ischemic Foot Ulcer","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"1984-01","conditions":"Ischemic Foot Ulcer","enrollment":91},{"nctId":"NCT03511521","phase":"PHASE4","title":"Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2018-03-27","conditions":"Hyperglycemia Steroid-induced, Insulin Resistance, Diabetes","enrollment":3},{"nctId":"NCT03862690","phase":"","title":"A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria","status":"WITHDRAWN","sponsor":"Novo Nordisk A/S","startDate":"2020-05-28","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT02284009","phase":"PHASE2","title":"Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-10","conditions":"Diabetes Mellitus, Type 1","enrollment":67},{"nctId":"NCT03013985","phase":"PHASE4","title":"Glargine U300 Hospital Trial","status":"COMPLETED","sponsor":"Emory University","startDate":"2017-05-17","conditions":"Type 2 Diabetes","enrollment":247},{"nctId":"NCT04226378","phase":"","title":"Canadian Real-World Outcomes of Omnipod Initiation in People With T1D","status":"COMPLETED","sponsor":"LMC Diabetes & Endocrinology Ltd.","startDate":"2020-01-20","conditions":"Diabetes Mellitus, Type 1","enrollment":286},{"nctId":"NCT02814123","phase":"PHASE2","title":"Effect of Basal-Bolus Closed-Loop Co-Administration of Insulin and Pramlintide on Improving the Glycemic Control in Type 1 Diabetes","status":"COMPLETED","sponsor":"McGill University","startDate":"2017-01-13","conditions":"Diabetes Mellitus, Type 1","enrollment":28},{"nctId":"NCT04237129","phase":"PHASE1","title":"PK/PD Study of Gan & Lee Insulin Aspart Injection vs. US & EU NovoLog®/NovoRapid® in Healthy Males","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2019-08-27","conditions":"Diabetes Mellitus, Type 1","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":938,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["glargine","glulisine","Basal insulin glargine","Pre-meal insulin lispro"],"phase":"phase_3","status":"active","brandName":"Basal Insulin and Bolus Insulin","genericName":"Basal Insulin and Bolus Insulin","companyName":"Rabin Medical Center","companyId":"rabin-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Basal-bolus insulin therapy mimics physiological insulin secretion by combining long-acting basal insulin for fasting glucose control with rapid-acting bolus insulin for postprandial glucose management. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus requiring intensive insulin therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}